USA flag logo/image

An Official Website of the United States Government

New Reagents for Synthesizing Nuclease-resistant siRNA

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
89210
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
GM084552
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AM BIOTECHNOLOGIES, LLC
12521 Gulf Freeway HOUSTON, TX 77034-4509
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: New Reagents for Synthesizing Nuclease-resistant siRNA
Agency: HHS
Contract: 1R43GM084552-01
Award Amount: $199,202.00
 

Abstract:

DESCRIPTION (provided by applicant): The siRNA molecule needs better protection from nuclease degradation before it can be effectively used as a therapeutic. AM Biotechnologies (AM) will address this critical issue by developing ribonucleoside thiophospho ramidite (ABz, CBz, GIbu and U) reagents that will enable synthesis of phosphorodithioate siRNA (PS2-siRNA). This synthesized PS2-siRNA will significantly increase siRNA nuclease resistance; lower Tm, which could help the activated RISC unwind siRNA; and e nhance the pharmacokinetic properties of siRNA. The PS2-siRNA will also be achiral at phosphorus, which will eliminate the variable biochemical, biophysical, and biological properties of diastereomeric phosphoromonothioate substituted siRNAs (PS-siRNAs). I n this Phase I SBIR project, AM will: 1) develop the chemistry and optimize the conditions to produce four ribonucleoside thiophosphoramidites (ABz, CBz, GIbu and U); 2) demonstrate high coupling yield (gt97%) in the synthesis of PS2-siRNAs; and 3) evaluat e PS2-siRNA gene silencing effect in vitro. In Phase II, AM will perform the research required to (a) scale reagent production up to commercial quantities and purity; (b) optimize a robust protocol for synthesis of PS2-siRNA; (c) systematically evaluate th e positional effect of PS2 modification on siRNA activity in mammalian cells; (d) examine the bio-distribution of PS2-siRNA; and (e) fully characterize the pharmacokinetic properties of PS2-siRNA. AM in Phase II may also offer for sale limited quantities o f research-grade reagents for market beta testing. Upon successful completion of Phase II, AM will work with its industry partners to commercialize the ribonucleoside thiophosphoramidites (R-thioamidites) and enable the entire life science community to ben efit from the use of these unique reagents.

Principal Investigator:

Business Contact:


mark.shumbera@thioaptamer.com
Small Business Information at Submission:

AM BIOTECHNOLOGIES, LLC
AM BIOTECHNOLOGIES, LLC 12521 Gulf Freeway Houston, TX 77034

EIN/Tax ID: 205252359
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No